Alpha interferon as first line therapy for angioimmunoblastic lymphoadenopathy. Possible value of DR+ cells in monitoring therapeutical response.
Milone
G
G
Guglielmo
P
P
Cacciola
E
E
Calogero
D
D
Giustolisi
R
R
D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers; D006684:HLA-DR Antigens / Q000032:analysis*; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000628:therapy*; D007155:Immunologic Factors / Q000627:therapeutic use*; D016130:Immunophenotyping; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D016131:Lymphocyte Subsets / Q000276:immunology*; D008297:Male; D011994:Recombinant Proteins; D012074:Remission Induction
D015415:Biomarkers; D006684:HLA-DR Antigens; D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins